AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

被引：0
|
作者：
Pemovska, T. [1 ]
Johnson, E. [2 ]
Kontro, M. [3 ,4 ]
Repasky, G. A. [1 ]
Chen, J. [2 ]
Wells, P. [2 ]
Cronin, C. [2 ]
McTigue, M. [2 ]
Kallioniemi, O. [1 ]
Porkka, K. [3 ,4 ]
Murray, B. W. [2 ]
Wennerberg, K. [1 ]
机构：
[1] Univ Helsinki, FIMM, Helsinki, Finland
[2] Pfizer Worldwide Res & Dev, Oncol Res Unit, San Diego, CA USA
[3] Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
来源：
ANNALS OF HEMATOLOGY | 2015年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：S90 / S91
页数：2
相关论文
共 50 条
  • [1] AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion
    Pemovska, T.
    Johnson, E.
    Kontro, M.
    Repasky, G. A.
    Chen, J.
    Wells, P.
    Cronin, C.
    McTigue, M.
    Kallioniemi, O.
    Porkka, K.
    Murray, B. W.
    Wennerberg, K.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 90 - 91
  • [2] Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion
    Pemovska, Tea
    Johnson, Eric
    Kontro, Mika
    Repasky, Gretchen A.
    Chen, Jeffrey
    Wells, Peter
    Cronin, Ciaran N.
    McTigue, Michele
    Kallioniemi, Olli
    Porkka, Kimmo
    Murray, Brion W.
    Wennerberg, Krister
    CANCER RESEARCH, 2015, 75
  • [3] Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
    Tea Pemovska
    Eric Johnson
    Mika Kontro
    Gretchen A. Repasky
    Jeffrey Chen
    Peter Wells
    Ciarán N. Cronin
    Michele McTigue
    Olli Kallioniemi
    Kimmo Porkka
    Brion W. Murray
    Krister Wennerberg
    Nature, 2015, 519 : 102 - 105
  • [4] Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
    Pemovska, Tea
    Johnson, Eric
    Kontro, Mika
    Repasky, Gretchen A.
    Chen, Jeffrey
    Wells, Peter
    Cronin, Ciaran N.
    McTigue, Michele
    Kallioniemi, Olli
    Porkka, Kimmo
    Murray, Brion W.
    Wennerberg, Krister
    NATURE, 2015, 519 (7541) : 102 - U225
  • [5] The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm
    Gibbons, Don L.
    Pricl, Sabrina
    Kantarjian, Hagop
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    CANCER, 2012, 118 (02) : 293 - 299
  • [6] The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo
    Pemovska, Tea
    Kontro, Mika
    Repasky, Gretchen A.
    Porkka, Kimmo
    Wennerberg, Krister
    CANCER RESEARCH, 2014, 74 (19)
  • [7] Targeting the PTP1B-Bcr-Abl1 interaction for the degradation of T315I mutant Bcr-Abl1 in chronic myeloid leukemia
    Elgehama, Ahmed
    Wang, Yixuan
    Yu, Ying
    Zhou, Lin
    Chen, Zhixiu
    Wang, Liwei
    Sun, Lijun
    Gao, Jian
    Yu, Biao
    Shen, Yan
    Xu, Qiang
    CANCER SCIENCE, 2023, 114 (01) : 247 - 258
  • [8] BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
    Erdmann, Robert
    Jorgensen, Heather
    Ben-Batalla, Isabel
    Kruse, Nils
    Micklem, David
    von Amsberg, Gunhild
    Schafhausen, Philippe
    Schultze, Alexander
    Wroblewski, Mark
    Binder, Mascha
    Cubas-Cordova, Miguel
    Hadlich, Tobias
    Janning, Melanie
    Sawall, Stefanie
    Gensch, Victoria
    Allan, Elaine K.
    Mukherjee, Leena
    Morrison, Heather
    Cassells, Jennifer
    Kroeger, Nicolaus
    Lorens, James
    Clark, Richard E.
    Koschmieder, Steffen
    Vandenberghe, Peter
    Bruemmendorf, Tim H.
    Hochhaus, Andreas
    Carmeliet, Peter
    Holyoake, Tessa L.
    Pantel, Klaus
    Bokemeyer, Carsten
    Loges, Sonja
    BLOOD, 2014, 124 (21)
  • [9] Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia
    Mughal, Tariq I.
    Goldman, John M.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S81 - S84
  • [10] A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl
    Choi, Hwan Geun
    Ren, Pingda
    Adrian, Francisco
    Sun, Fangxian
    Lee, Hyun Soo
    Wang, Xia
    Ding, Qiang
    Zhang, Guobao
    Xie, Yongping
    Zhang, Jianming
    Liu, Yi
    Tuntland, Tove
    Warmuth, Markus
    Manley, Paul W.
    Mestan, Juergen
    Gray, Nathanael S.
    Sim, Taebo
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (15) : 5439 - 5448
12345